It will showcase these products, in addition to its chromatography solutions at ASMS 2021
Thermo Fisher Scientific, has introduced updated mass spectrometry instruments, workflows and software. The company will showcase these additions to its offering during the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, to be held October 31-November 4, in the Pennsylvania Convention Center.
"The life science industry has stepped forward in an unprecedented fashion over the last 18 months, with academia and biopharma making key contributions to respond to the pandemic," said Dan Shine, Senior VP and President, Analytical Instruments, Thermo Fisher Scientific. "We’re honored to have played an essential role in this effort. The new instruments, software and workflows that we're unveiling today will further support innovation across proteomics, biopharmaceutical characterisation and data acquisition while also ensuring that scientists can continue their critical ongoing research."
The Orbitrap Exploris MX mass detector allows biopharmaceutical laboratories to implement multi-attribute method (MAM), and perform intact analysis of monoclonal antibodies, oligonucleotide mass determination and peptide mapping. To simplify the transition of biotherapeutics from development to manufacturing, the system enables QC customers to use the same method established earlier in a molecule’s journey to commercialisation, accelerating the biopharmaceutical pipeline. The updated system reportedly offers superior data quality and, therefore, high-confidence results, even for users with limited mass spectrometric experience.
The MAM 2.0 workflow streamlines biopharmaceutical characterisation, process monitoring and release testing by replacing multiple traditional assays with one comprehensive analysis, delivering insights on multiple critical product quality attributes. MAM 2.0 includes the training, on-going support and partnership required for laboratories to enhance their analytical workflows across R&D, manufacturing and QC environments. To remove the bottlenecks often seen by organisations moving therapeutics from development to manufacturing, the new workflow enables the use of the same platform throughout the entire process, ultimately creating an end-to-end solution allowing for the seamless transfer of data and knowledge across teams and departments.
For proteomics researchers, the combination of Proteome Discoverer 3.0 software with CHIMERYS by MSAID will greatly increase their ability to identify peptides and proteins, allowing for a wider and deeper understanding of biological systems. By leveraging artificial intelligence (AI) to reimagine the analysis of tandem mass spectra, peptide coverage and quantitation capabilities are increased, unlocking possibilities for proteomics researchers.
To provide scientists performing small molecule analysis in metabolomics, environmental, food safety, clinical and forensics laboratories with faster and more sensitive compound detection, the Compound Discoverer 3.3 software offers an enhanced peak detection algorithm and improved peak quality rating.
The BioPharma Finder 5.0 software creates capabilities for biotherapeutic workflows by increasing analytical throughput and confidence through built for purpose data processing, curation and customisable reporting. The secure environment enables global collaboration and can be used across multiple application workflows, such as peptide mapping analysis, oligonucleotide analysis, intact mass analysis and top down analysis.
Finally, the Thermo Scientific LipidSearch 5.0 software now supports direct infusion workflows and features a database of 1.5 million lipids, enabling real time monitoring in addition to more accurate lipid quantitation.